Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma
- PMID: 39739260
- DOI: 10.1245/s10434-024-16742-3
Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma
Abstract
Background: This study aimed to evaluate the immunotherapeutic effect of irreversible electroporation (IRE) and IP-001 in pancreatic adenocarcinoma with metastasis.
Methods: Orthotopic models of pancreatic adenocarcinoma with hepatic oligometastasis were established by implantation of tumor tissues (derived from Pan02 or KPC cells) size 2 mm3 into the pancreas and left liver lobe in C57BL/6J mice. One week after implantation, the tumor-burden mice were subjected to saline control, IRE, IP-001, and IRE+IP-001. For IRE therapy (1000 V, 0.1 ms, 10 pulses administered 10 times), the pancreas tumor was treated, whereas the oligometastasis was untreated as the IRE off-target tumor. Intratumoral administration of IP-001(0.4 ml/kg) was performed.
Results: In the KPC oligometastatic model, IRE+IP-001 therapy significantly suppressed the growth of oligometastatic tumor. Flow cytometry showed significantly increased tumor-infiltrating lymphocytes (TILs) (e.g., CD8+ cytotoxic T lymphocytes) and significantly increased monocytes/macrophages in the oligometastatic tumor tissues from IRE+IP-001 treatment compared with the sham control. Significantly decreased Treg cells and tumor-associated macrophages (TAMs) also were found in the oligometastatic tumor tissues from IRE+IP-001 treatment compared with the sham control. In the Pan02 oligometastatic model, both IRE+IP-001 therapy and IRE+anti-PD-L1 immunotherapy significantly suppressed the growth of oligometastatic tumor, which was associated with the increased CD8+ cytotoxic T lymphocytes. However, increased monocytes/macrophages were found in the mice that had IRE+IP-001 therapy, but not in the mice that had IRE+anti-PD-L1 immunotherapy.
Conclusion: The study provided compelling evidence for the efficacy of IRE&IP-001 therapy in suppressing pancreatic tumors, including off-target oligometastatic lesions. The observed off-target effect underscores the importance of systemic immune activation in achieving effective tumor control.
Keywords: IP-001; Immune-modulation; Irreversible electroporation; N‐dihydrogalactochitosan; Pancreatic adenocarcinoma.
© 2024. Society of Surgical Oncology.
Conflict of interest statement
Disclosure: Immunophotonics provided the IP-001 as an unrestricted educational grant. Robert C. Martin is a paid educational consultant for Angiodynamics, a manufacturer of IRE. Samuel S. K. Lam is a full-time employee of Immunophotonics, Inc and one of the authors listed in one of the IPs of IP-001. David Anderson is an employee of Immunophotonics and a shareholder. The remaining authors have no conflicts of interest.
Similar articles
-
Comparative Analysis of Systemic Immune Responses and Metastatic Risks in Tumor Ablation: An Animal Study of Radiofrequency Ablation and Irreversible Electroporation with Immune Modulation.Cardiovasc Intervent Radiol. 2025 Apr;48(4):524-535. doi: 10.1007/s00270-024-03938-z. Epub 2025 Jan 9. Cardiovasc Intervent Radiol. 2025. PMID: 39789251
-
A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.Surgery. 2020 Oct;168(4):610-616. doi: 10.1016/j.surg.2020.04.057. Epub 2020 Jul 4. Surgery. 2020. PMID: 32631655 Clinical Trial.
-
Irreversible electroporation combined with PD-L1/IL-6 dual blockade promotes anti-tumor immunity via cDC2/CD4+T cell axis in MHC-I deficient pancreatic cancer.Cancer Lett. 2025 May 1;617:217620. doi: 10.1016/j.canlet.2025.217620. Epub 2025 Mar 9. Cancer Lett. 2025. PMID: 40068706
-
Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers?Hepatobiliary Pancreat Dis Int. 2019 Apr;18(2):117-124. doi: 10.1016/j.hbpd.2019.01.001. Epub 2019 Jan 4. Hepatobiliary Pancreat Dis Int. 2019. PMID: 30655073 Review.
-
Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery.J Surg Oncol. 2016 Dec;114(7):865-871. doi: 10.1002/jso.24404. Epub 2016 Aug 21. J Surg Oncol. 2016. PMID: 27546233
References
-
- Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistic Review, 1975–2017. Bethesda, MD: National Cancer Institute; 2019.
-
- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703. - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials